Integrated Filing — IndAS

General information about company
Scrip Code	532488
NSE Symbol	DIVISLAB
MSEI Symbol	NOTLISTED
ISIN	INE361B01024
Name of company	Divi's Laboratories Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	17-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	08-May-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients
Start date and time of board meeting	17-May-2025   11:15:00
End date and time of board meeting	17-May-2025   12:55:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	25850000000	93600000000
	Other income	860000000	3520000000
	Total income	26710000000	97120000000
2	Expenses
(a)	Cost of materials consumed	9310000000	38210000000
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	500000000	-960000000
(d)	Employee benefit expense	3500000000	12430000000
(e)	Finance costs	10000000	20000000
(f)	Depreciation, depletion and amortisation expense	1070000000	4020000000
(f)	Other Expenses
1	Other expenses	3680000000	14240000000
	Total other expenses	3680000000	14240000000
	Total expenses	18070000000	67960000000
3	Total profit before exceptional items and tax	8640000000	29160000000
4	Exceptional items	0	0
5	Total profit before tax	8640000000	29160000000
6	Tax expense
7	Current tax	2280000000	7990000000
8	Deferred tax	-260000000	-740000000
9	Total tax expenses	2020000000	7250000000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	6620000000	21910000000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	6620000000	21910000000
17	Other comprehensive income net of taxes	0	30000000
18	Total Comprehensive Income for the period	6620000000	21940000000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent	6620000000	21910000000
	Total profit or loss, attributable to non-controlling interests	0	0
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent	6620000000	21940000000
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
21	Details of equity share capital
	Paid-up equity share capital	530000000	530000000
	Face value of equity share capital	2	2
27	Details of debt securities
22	Reserves excluding revaluation reserve		149160000000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	24.93	82.53
	Diluted earnings (loss) per share from continuing operations	24.93	82.53
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	24.93	82.53
	Diluted earnings (loss) per share from continuing and discontinued operations	24.93	82.53
24	Debt equity ratio
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results		n1.tThe above Statement of consolidated audited financial results for the quarter and year ended March 31, 2025, Consolidated audited statement of assets and liabilities and Consolidated audited statement of cash flows as at and for the year ended March 31, 2025 ('Consolidated Statements') are prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('lndAS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Consolidated statements have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 17, 2025. The statutory auditors have audited the consolidated statements and issued an unmodified report thereon. n2.tThe consolidated financial results include the financial results of the wholly owned subsidiaries viz., Divis Laboratories (USA) Inc and Divi’s Laboratories Europe AG. n3.tThe Group is engaged in the manufacture of Active Pharmaceutical Ingredients, intermediates and nutraceutical ingredients; and the same constitutes a single reportable business segment as per Ind AS 108. n4.tThe Group does not have any discontinued operations and the Profit for the year represents the Profits from continuing operations only. n5.tThe Unit III greenfield project at Ontimamidi village, near Kakinada, Andhra Pradesh, of the Parent Company has commenced commercial operations in the current quarter. n6.tThe Parent Company has decided to exercise the option permitted in the section 115BAA of the Indian Income Tax Act, 1961 from the current financial year. The tax expense for the year ended March 31,2025 are estimated accordingly. n7.t**Financial results for the quarter ended March 31, 2025 and corresponding quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the respective financial years which were subject to limited review. n8.tThe Board of Directors of the company has recommended a dividend of Rs. 30 per share of face value Rs. 2/- each i.e. 1500 percent for the financial year 2024-25, subject to approval of members at the ensuing annual general meeting. n9.tDetails of forex gain/(loss) are as given below: (Rs. in Crores) ntQuarter endedtYear Ended nt31.03.2025t31.12.2024t31.03.2024t31.03.2025t31.03.2024 nt(Audited)**t(Unaudited)t(Audited)**t(Audited)t(Audited) nForex gain/ (loss) t10t10t(2)t48t30 n Forex gain has been included in Other Income and loss has been included in Other Expenses. n

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Consolidated
	Assets
1	Non-current assets
	Property, plant and equipment	54370000000
	Capital work-in-progress	10220000000
	Investment property
	Goodwill	0
	Other intangible assets	40000000
	Intangible assets under development
	Biological assets other than bearer plants
	Investments accounted for using equity method
	Non-current financial assets
	Non-current investments	650000000
	Trade receivables, non-current
	Loans, non-current	0
	Other non-current financial assets	620000000
	Total non-current financial assets	1270000000
	Deferred tax assets (net)	110000000
	Other non-current assets	2500000000
	Total non-current assets	68510000000
2	Current assets
	Inventories	32360000000
	Current financial asset
	Current investments	0
	Trade receivables, current	27310000000
	Cash and cash equivalents	4150000000
	Bank balance other than cash and cash equivalents	33000000000
	Loans, current	0
	Other current financial assets	160000000
	Total current financial assets	64620000000
	Current tax assets (net)
	Other current assets	3830000000
	Total current assets	100810000000
3	Non-current assets classified as held for sale
4	Regulatory deferral account debit balances and related deferred tax Assets
	Total assets	169320000000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	530000000
	Other equity	149160000000
	Total equity attributable to owners of parent	149690000000
	Non controlling interest
	Total equity	149690000000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	0
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
	Total Trade payable
	Other non-current financial liabilities	20000000
	Total non-current financial liabilities	20000000
	Provisions, non-current	0
	Deferred tax liabilities (net)	5090000000
	Deferred government grants, Non-current
	Other non-current liabilities
	Total non-current liabilities	5110000000
	Current liabilities
	Current financial liabilities
	Borrowings, current	20000000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	370000000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	8730000000
	Total Trade payable	9100000000
	Other current financial liabilities	1340000000
	Total current financial liabilities	10460000000
	Other current liabilities	3520000000
	Provisions, current	540000000
	Current tax liabilities (Net)
	Deferred government grants, Current
	Total current liabilities	14520000000
3	Liabilities directly associated with assets in disposal group classified as held for sale
4	Regulatory deferral account credit balances and related deferred tax liability
	Total liabilities	19630000000
	Total equity and liabilites	169320000000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Consolidated	Consolidated
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Gain/loss on Remeasurement of post-employment benefit obligations	-10000000	-30000000
	Total Amount of items that will not be reclassified to profit and loss	-10000000	-30000000
2	Income tax relating to items that will not be reclassified to profit or loss	0	10000000
3	Amount of items that will be reclassified to profit and loss
1	i)tGain/(loss) on exchange differences in translating the financial statements of foreign operations	10000000	60000000
	Total Amount of items that will be reclassified to profit and loss	10000000	60000000
4	Income tax relating to items that will be reclassified to profit or loss	0	-10000000
5	Total Other comprehensive income	0	30000000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Consolidated
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			29160000000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			20000000
	Adjustments for decrease (increase) in inventories			-520000000
	Adjustments for decrease (increase) in trade receivables, current			-5820000000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			-500000000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			-60000000
	Adjustments for other financial assets, current			-90000000
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			950000000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			430000000
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			4020000000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			-20000000
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			70000000
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			90000000
	Adjustments for dividend income			0
	Adjustments for interest income			2950000000
	Adjustments for share-based payments			0
	Adjustments for fair value losses (gains)			-10000000
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			-40000000
	Other adjustments to reconcile profit (loss)			0
	Other adjustments for non-cash items			40000000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			-4390000000
	Net cash flows from (used in) operations			24770000000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			8240000000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			16530000000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			0
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			0
	Purchase of property, plant and equipment			14380000000
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			2950000000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			3390000000
	Net cash flows from (used in) investing activities	-8040000000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			0
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			0
	Repayments of borrowings			0
	Payments of lease liabilities			10000000
	Dividends paid			7960000000
	Interest paid			20000000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			-7990000000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			500000000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			0
	Net increase (decrease) in cash and cash equivalents			500000000
	Cash and cash equivalents cash flow statement at beginning of period			3630000000
	Cash and cash equivalents cash flow statement at end of period			4130000000